Biopharma deal making in 2024 and 2025
Where pharma is investing for the future of medicine
Biopharma dealmaking is undergoing a fundamental transformation. Economic headwinds, evolving regulatory scrutiny, and shifting therapeutic priorities have redrawn the industry’s investment map. Our annual Deals Report offers a comprehensive view of how companies, large and small, are adapting. Whether you’re planning an acquisition, preparing for licensing negotiations, or navigating capital markets, this report delivers the strategic intelligence you need to move forward with confidence.
Key insights include:
- Strategic shift toward bolt-on acquisitions and early-stage assets
- Surge in oncology investments, including ADCs and radiopharmaceuticals
- Cross-border licensing boom, with China at the forefront
- Regulatory and geopolitical headwinds executives can’t ignore
- How industry leaders are adapting to an activist FTC and policy uncertainty
Download the report to find out more.
